Trial reportMovement disorders : official journal of the Movement Disorder Society2018
Speech treatment in Parkinson's disease: Randomized controlled trial (RCT).
Trial report in Movement disorders : official journal of the Movement Disorder Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Genome-Wide Meta-Analysis of Parkinson's Disease Associated Genetic Loci and Validation of Therapeutic Targets.Brain and behavior · 2025Pooled it
- Effectiveness of Telerehabilitation on Motor Impairments, Non-motor Symptoms and Compliance in Patients With Parkinson's Disease: A Systematic Review.Frontiers in neurology · 2021Pooled it
- Baseline predictors of response to a group-based speech and communication intervention in Parkinson's disease: A secondary analysis of a randomized controlled trial.Journal of Parkinson's disease · 2026Trial
- "YiJinJing, Wohu Pushi" Posture-Voice Therapy for Dysarthria in Parkinson's Disease Patients Following Subthalamic Nucleus Deep Brain Stimulation: A Randomized Controlled Trial.CNS neuroscience & therapeutics · 2025Trial
- Speech Treatment for People with Cerebellar Multiple System Atrophy (MSA-C): A Pilot Randomised Controlled Trial of Two Approaches.Cerebellum (London, England) · 2025Trial
- Speech Treatment for People with Cerebellar Multiple System Atrophy (MSA-C): A Pilot Randomised Controlled Trial of Two Approaches.Cerebellum (London, England) · 2025Trial
- Comparing face-to-face and online LSVT®LOUD speech training using LSVT®Coach in patients with Parkinson's disease: a pilot randomised controlled trial.BMC neurology · 2025Trial
- The Acoustic Voice Quality Index (AVQI) in People with Parkinson's Disease Before and After Intensive Voice and Articulation Therapies: Secondary Outcome of a Randomized Controlled Trial.Journal of voice : official journal of the Voice Foundation · 2024Trial
- Lee Silverman voice treatment versus NHS speech and language therapy versus control for dysarthria in people with Parkinson's disease (PD COMM): pragmatic, UK based, multicentre, three arm, parallel group, unblinded, randomised controlled trial.BMJ (Clinical research ed.) · 2024Trial
- Crowdsourced Perceptual Ratings of Voice Quality in People With Parkinson's Disease Before and After Intensive Voice and Articulation Therapies: Secondary Outcome of a Randomized Controlled Trial.Journal of speech, language, and hearing research : JSLHR · 2023Trial
- Immediate and long-term effects of speech treatment targets and intensive dosage on Parkinson's disease dysphonia and the speech motor network: Randomized controlled trial.Human brain mapping · 2022Trial
- Not always the usual suspect: symptom variations in Parkinson's disease beyond ON-OFF fluctuations.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Breathe, Eat, Talk: Three Essential Ingredients to Quality-of-Life Outcomes in Movement Disorders.Movement disorders clinical practice · 2026Review
- Voice and Speech in Atypical Parkinsonian Disorders.Movement disorders clinical practice · 2026Review
- Aerodynamic and Acoustic Characteristics of Nasal Airflow in Parkinson's Disease.Journal of speech, language, and hearing research : JSLHR · 2026Article
- Preventing Parkinson's disease in the context of movement disorders: a narrative review of current evidence and future directions.Neurological research and practice · 2026Review
- Practice Parameters That Influence Vocal Motor Adaptation in Altered Auditory Feedback Paradigms.Journal of speech, language, and hearing research : JSLHR · 2026Article
- Sensorimotor Adaptation to a Nonuniform Formant Perturbation Is Preserved in Healthy Aging.Journal of speech, language, and hearing research : JSLHR · 2026Article
- Development and validation of the dysarthria impact scale: a patient-reported outcome for motor speech disorders.Journal of neurology · 2026Article
- Voice-Assisted Technology for People With Parkinson's Disease Experiencing Speech and Voice Difficulties: Co-Designing Solutions Using Design Thinking.JMIR rehabilitation and assistive technologies · 2026Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAs many as 89% of people with Parkinson's disease (PD) develop speech disorders.
objectivesThis randomized controlled trial evaluated two speech treatments for PD matched in intensive dosage and high-effort mode of delivery, differing in subsystem target: voice (respiratory-laryngeal) versus articulation (orofacial-articulatory).
methodsPD participants were randomized to 1-month LSVT LOUD (voice), LSVT ARTIC (articulation), or UNTXPD (untreated) groups. Speech clinicians specializing in PD delivered treatment. Primary outcome was sound pressure level (SPL) in reading and spontaneous speech, and secondary outcome was participant-reported Modified Communication Effectiveness Index (CETI-M), evaluated at baseline, 1, and 7 months. Healthy controls were matched by age and sex.
resultsAt baseline, the combined PD group (n = 64) was significantly worse than healthy controls (n = 20) for SPL (P < 0.05) and CETI-M (P = 0.0001). At 1 and 7 months, SPL between-group comparisons showed greater improvements for LSVT LOUD (n = 22) than LSVT ARTIC (n = 20; P < 0.05) and UNTXPD (n = 22; P < 0.05). Sound pressure level differences between LSVT ARTIC and UNTXPD at 1 and 7 months were not significant (P > 0.05). For CETI-M, between-group comparisons showed greater improvements for LSVT LOUD and LSVT ARTIC than UNTXPD at 1 month (P = 0.02; P = 0.02). At 7 months, CETI-M between-group differences were not significant (P = 0.08). Within-group CETI-M improvements for LSVT LOUD were maintained through 7 months (P = 0.0011).
conclusionsLSVT LOUD showed greater improvements than both LSVT ARTIC and UNTXPD for SPL at 1 and 7 months. For CETI-M, both LSVT LOUD and LSVT ARTIC improved at 1 month relative to UNTXPD. Only LSVT LOUD maintained CETI-M improvements at 7 months. © 2018 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.